They must also investigate how long any improvement lasts. We will judge this work by the quality of the evidence. Our next announcement expands research beyond ibogaine The National Institute of Mental Health has opened a $20 million funding opportunity to establish a research network focused on rapid action psychotropic drugs. The network will study treatments including ketamine, esketamine, psilocybin and other emerging approaches or serious mental illness. NIMH expects to announce award recipients in the summer of 2027. (12:55–13:08)
STATEMENT
Asserts that NIMH has opened a $20 million funding opportunity for a research network on rapid action psychotropic drugs.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.